Allergan Drug Buyers' Renewed Bid For Cert. Deemed 'Futile'
Purchasers of Allergan's ulcerative colitis drug won't get a second crack at class certification in their antitrust suit, as a Massachusetts federal judge has found their renewed effort would likely look...To view the full article, register now.
Already a subscriber? Click here to view full article